2021年6月3日 · Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy; approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1...

2023年10月2日 · Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult acute myeloid leukemia (AML) and less commonly in pediatric AML. The objective of this study was to describe the prevalence, mutational profile, and prognostic significance of IDH mutations in AML across age.

2023年2月3日 · Multiple inhibitors targeting mutated IDH are being developed, including ivosidenib (AG-120) and enasidenib (AG-221), which have already been approved by the US Food and Drug Administration (FDA) for patients with IDH1- and IDH2-mutated AML, respectively, allowing a targeted treatment option for these patients. 15-17 Furthermore, IDH-mutated ...

2024年4月10日 · In this review, we outline the role of IDH mutations in malignant transformation, focus in on a novel group of targeted therapeutic agents directed toward IDH1 - and IDH2 -mutant AML, and...

目前 IDH1靶向药 艾伏尼布 已经在我国上市，它通过与突变IDH1可逆性结合，降低肿瘤代谢物2-HG水平，促进细胞正常分化，从而发挥抗肿瘤作用，同时又可有效避免骨髓抑制、降低感染风险。 目前国内艾伏尼布的价格是69800元一盒，规格是每盒0.25g*60片，还没有纳入医保，患者需要自费。 IDH2靶向药 恩西地平 可降低2-HG的含量从而诱导白血病细胞分化，国外已上市，目前尚未在我国上市。 据了解恩西地平中国香港版价格 278800元左右，规格为100mg*30片一盒。 …

2022年11月15日 · Despite improving treatment for hematological malignancies, advanced acute myeloid leukemia is associated with a poor prognosis. In this systematic review, we assessed the efficacy and safety of IDH 1 and 2 inhibitors used alone or in combination with other drugs in IDH 1 and 2 mutated AML.

Isocitrate dehydrogenases (IDHs) are enzymes involved in multiple metabolic and epigenetic cellular processes. Mutations in IDH1 or IDH2 are detected in approximately 20% of patients with acute myeloid leukemia (AML) and induce amino acid changes in conserved residues resulting in neomorphic enzymat …

2023年10月10日 · Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult acute myeloid leukemia (AML) and less commonly in pediatric AML. The objective of this study was to describe the prevalence, mutational profile, and prognostic significance of IDH mutations in AML across age.

2023年7月7日 · 《Blood Advances》近日发表一项研究，旨在描述 IDH 突变在不同年龄范围的大型 AML 队列中的发病率、共突变（co-occurring mutation）特征和预后影响。 作者还假设，提高对 IDH 突变 AML 的理解，将实现靶向药物最佳整合到风险和年龄分层治疗策略中。 研究结果. 该研究共纳入不同研究（CCG/COG、SWOG、ECOG等）中的3141例年龄介于<1个月到88岁的AML患者，根据年龄分为四组：儿童 (0-17岁，n=1744)、青少年/年轻成人 (AYA) (18-39 …

2023年7月11日 · We performed a comprehensive analysis of the efficacy of two IDH inhibitor regimens (IDH inhibitor combination and IDH inhibitor alone) in two populations (newly diagnosed IDH-mutated AML patients and R/R IDH-mutated AML …